Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
Crossref DOI link: https://doi.org/10.1007/s00280-015-2691-1
Published Online: 2015-02-13
Published Print: 2015-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hwang, In Gyu
Jang, Joung-Soon
Oh, Sung Yong
Rho, Myung Hwan
Lee, Suee
Park, Young Suk
Park, Joon Oh
Nam, Eun Mi
Lee, Hyo Rak
Jun, Hyun Jung
Chi, Kyong-Choun
Text and Data Mining valid from 2015-02-13